1. Home
  2. ENVX vs IMCR Comparison

ENVX vs IMCR Comparison

Compare ENVX & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enovix Corporation

ENVX

Enovix Corporation

HOLD

Current Price

$6.93

Market Cap

1.4B

Sector

Miscellaneous

ML Signal

HOLD

Logo Immunocore Holdings plc

IMCR

Immunocore Holdings plc

HOLD

Current Price

$29.35

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENVX
IMCR
Founded
2006
2008
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.7B
IPO Year
2020
2016

Fundamental Metrics

Financial Performance
Metric
ENVX
IMCR
Price
$6.93
$29.35
Analyst Decision
Buy
Buy
Analyst Count
9
10
Target Price
$13.61
$66.33
AVG Volume (30 Days)
5.2M
356.8K
Earning Date
05-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
40.94
30.39
EPS
N/A
0.25
Revenue
$31,821,000.00
$249,428,000.00
Revenue This Year
$30.37
$14.57
Revenue Next Year
$238.73
$8.21
P/E Ratio
N/A
$115.36
Revenue Growth
37.91
43.05
52 Week Low
$4.67
$27.47
52 Week High
$16.49
$40.71

Technical Indicators

Market Signals
Indicator
ENVX
IMCR
Relative Strength Index (RSI) 58.91 46.82
Support Level $6.68 $28.90
Resistance Level $8.66 $34.35
Average True Range (ATR) 0.44 1.32
MACD -0.00 0.11
Stochastic Oscillator 61.94 46.62

Price Performance

Historical Comparison
ENVX
IMCR

About ENVX Enovix Corporation

Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, the United States, Norway, Taiwan, and other regions.

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Share on Social Networks: